ALSO NOTED: Altana drops Xifaxan pact; Biovitrum buying Arexis; Harvard scientists make embryo breakthrough; and much more...

> Salix Pharmaceuticals has agreed to let Altana Pharma US, the US affiliate of the German company, out of its pact to co-market Xifaxan for traveler's diarrhea. Altana is switching its focus to respiratory products. Salix says that Altana's pullout won't affect its projected revenue figures for the year. Report

> Biovitrum is buying Sweden's Arexis, which develops drugs for metabolic and inflammatory diseases, for an undisclosed amount. Arexis was founded six years ago. Release

> Scientists at Harvard say they have created stem cells similar to embryonic cells without destroying embryos. The hybrid cell could offer a detour around the fierce debate over the use of embryonic stem cells in research. Report

> The FDA has approved a new formulation of Alphagan. Release

> Aventis Pharma has received approval for a new indication for Taxotere. Article

> Chutes & Ladders: Four of Seattle-based Cell Therapeutics' board members have resigned. Release

> Progenics Pharmaceuticals has added to the positive data from its earlier announced Phase III results for methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced medical illness. Report

And Finally... New York City health officials have been scrambling to craft a plan to handle an outbreak of avian flu. Article

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.